KERX Keryx Biopharmaceuticals Inc.

Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference

Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference

BOSTON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will participate in the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 in New York.

At the conference, Keryx will be participating in a 25 minute panel discussion titled Renal Anemia on Tuesday, October 2, 2018 at 3:30 p.m. Eastern time at the Sofitel New York in New York City.

A live audio webcast of both the panel discussion will be accessible from Keryx’s website at within the Investor Relations section under “events and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the panel discussion.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc., headquartered in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia (ferric citrate) tablets. For more information about Keryx, please visit .

KERYX BIOPHARMACEUTICALS CONTACT

Emily Beaulieu

Coordinator, Corporate Communications/Digital Media

 

EN
01/10/2018

Underlying

KERXKeryx Biopharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Keryx Biopharmaceuticals Inc.

 PRESS RELEASE
Free
KERX Keryx Biopharma...

Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Thera...

Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter alia Akebia Therapeutics, Inc. Separately today, Akebia announced that its stockholders voted to approve the share issuance proposal relating to the merger with Keryx at a special meeting of Akebia stockholders. “The...

December 11, 2018 1 EN
 PRESS RELEASE
Free
KERX Keryx Biopharma...

Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote...

Glass Lewis Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics BOSTON, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends Keryx stockholders vote “FOR” the proposals relating to the proposed merger with Akebia Therapeutics, Inc. (Nasdaq: AKBA) at the Special Meeting of Keryx stockholders to be held...

November 30, 2018 1 EN
 PRESS RELEASE
Free
KERX Keryx Biopharma...

ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR...

ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics Leading proxy advisory firm recognizes the strategic and financial merits of the merger BOSTON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) recommends Keryx stockholders vote “FOR” the merger and the proposals relating to the propos...

November 29, 2018 1 EN
 PRESS RELEASE
Free
KERX Keryx Biopharma...

Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Result...

Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results Third quarter 2018 total revenues of $28.0 million including net U.S. Auryxia® (ferric citrate) product sales of $26.6 million, a 96 percent increase compared to the third quarter of 2017Approximately 47,500 Auryxia Prescriptions were written in the third quarter of 2018, nearly double the number reported in the third quarter of 2017Merger with Akebia Therapeutics on track to close by year end, subject to stockholder approval and the satisfaction of other closing conditions BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- K...

November 8, 2018 1 EN
 PRESS RELEASE
Free
KERX Keryx Biopharma...

Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Resul...

Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018 BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will release its third quarter 2018 financial results on Thursday, November 8, 2018 at approximately 4:30 p.m. ET. Keryx will not be conducting a conference call in conjunction with its third quarter 2018 earnings release given its pending merger with Akebia Therapeutics, Inc. ...

November 6, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch